Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic, symmetrical polyarticular inflammation with a predilection for small joints of the hands and feet, resulting in progressive joint destruction and significant functional disability if untreated. RA is the most common inflammatory arthritis in developed countries, affecting approximately 0.5-1% of the adult population with a female-to-male ratio of 2.5-3:1 and peak onset in the fifth to sixth decades of life, though it can occur at any age. The disease is driven by autoimmune mechanisms targeting the synovial joint, with characteristic production of rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies, leading to progressive cartilage and bone destruction if inadequately treated. Early recognition and aggressive treatment with disease-modifying antirheumatic drugs (DMARDs) has dramatically improved outcomes, transforming RA from a disease of inevitable disability to one where sustained remission and normal life expectancy are achievable goals. RA remains a critical topic for board examinations and clinical practice due to its high prevalence, significant morbidity, requirement for early intervention, and substantial burden of systemic complications affecting the cardiovascular, pulmonary, and hematologic systems.

The pathogenesis of RA involves a complex interplay of genetic predisposition, environmental triggers, and loss of immune tolerance culminating in chronic synovial inflammation and joint destruction. The disease process unfolds through multiple integrated mechanisms:

The strongest genetic risk factor for RA is carriage of HLA-DR alleles containing the shared epitope (SE), particularly HLA-DRB1*04 alleles, which confer a 4-6 fold increased risk of disease development and are associated with more severe, erosive disease. Genome-wide association studies have identified additional genetic loci (PTPN22, STAT4, IL6) that increase susceptibility but explain only a modest proportion of the genetic contribution, indicating that environmental factors are essential for disease initiation. The shared epitope presents arthritogenic peptides to CD4+ T cells; individuals carrying these alleles who also develop anti-CCP antibodies face exponentially higher disease risk, suggesting a gene-environment interaction model where genetic susceptibility creates a permissive milieu for autoimmunity that requires environmental activation.

Central to RA pathogenesis is the production of anti-CCP antibodies, which precede clinical symptoms by years and target post-translational modifications of self-proteins created by peptidylarginine deiminase (PAD) enzymes that convert arginine residues to citrulline. Anti-CCP antibodies form immune complexes that deposit in synovial tissue and activate the complement system; these antibodies are highly specific for RA (95-98%) and appear in approximately 70% of cases, with seropositivity predicting more aggressive disease and greater radiographic progression. Rheumatoid factor (an anti-IgG antibody) is present in 80-85% of established RA and also forms immune complexes, though it is less specific than anti-CCP. Autoreactive CD4+ T cells recognizing citrullinated antigens expand in RA patients and promote B cell differentiation and plasma cell survival within germinal centers in synovial lymphoid aggregates, establishing self-sustaining autoimmune responses.

The synovial membrane transforms from a thin, largely acellular layer into a chronically inflamed tissue with massive cellular infiltration characterized by CD4+ T helper cells (particularly Th17 and Tfh cells), B cells producing antibodies and cytokines, and activated macrophages and fibroblasts. Th17 cells produce IL-17, which acts directly on synovial fibroblasts and osteoclast precursors to promote inflammatory cytokine production and bone resorption; this IL-17-dependent pathway is distinct from the classical Th1 pathway and represents a critical effector arm of RA pathology. The synovial lining becomes hyperplastic (pannus), composed of activated macrophages and fibroblasts that generate a pro-inflammatory microenvironment through production of TNF-α, IL-6, and IL-1β. These cytokines act in concert to amplify inflammation, promote endothelial activation and leukocyte recruitment, induce cyclooxygenase (COX)-2 expression leading to prostaglandin production, and drive activation of nuclear factor-kappa B (NF-κB) signaling in fibroblasts and immune cells.

The chronic inflammatory microenvironment directly drives destruction of articular cartilage and subchondral bone through multiple mechanisms: (1) matrix metalloproteinases (MMPs) and other collagenases are produced by synovial fibroblasts and macrophages in response to TNF-α and IL-1β, degrading the collagen and proteoglycan matrix of cartilage; (2) RANKL (receptor activator of NF-κB ligand) is upregulated on activated T cells, B cells, and synovial fibroblasts in response to TNF-α and IL-17, binding to RANK receptors on osteoclast precursors to promote osteoclastogenesis and bone resorption; (3) loss of TGF-β signaling (a normally protective mechanism) removes constraints on osteoclast differentiation. The erosive phase of RA is characterized by osteoclast-rich inflammatory infiltrates at the synovial-cartilage junction (pannus-cartilage interface) where bone-resorbing activity is greatest; early aggressive treatment that controls inflammation can prevent irreversible radiographic changes, as bone erosions do not repair once established.

The chronically inflamed synovium develops organized lymphoid architecture including ectopic germinal centers, follicular helper T cells (Tfh), and long-lived plasma cells that sustain local antibody production even during periods of systemic remission. These synovial lymphoid aggregates create a self-perpetuating immune response relatively resistant to systemic immunosuppression, explaining why some patients have persistent synovial inflammation despite achieved systemic remission. Additionally, citrullination of synovial proteins by activated PAD enzymes generates new epitopes recognized by B and T cells, creating intramolecular epitope spreading where the autoimmune response expands over time to target multiple citrullinated self-antigens.

RA is a primary autoimmune disease with no single etiology; rather, it results from the confluence of genetic susceptibility and environmental triggers in genetically predisposed individuals:

The strongest genetic associations are with HLA-DRB1 alleles encoding the shared epitope (particularly HLA-DRB1*04:01 and *04:04), which confer 4-6 fold increased disease risk in carriers and 20-fold risk in homozygotes compared to the general population. The shared epitope is present in approximately 70% of RA patients versus 25-30% of the general population, making it a marker of disease susceptibility rather than a necessary cause. Additional genetic loci identified through genome-wide association studies include PTPN22 (protein tyrosine phosphatase non-receptor type 22), STAT4 (signal transducer and activator of transcription 4), IL6, IL2RA, CDKN1A, and others, each conferring small increased odds ratios; the heritability of RA is estimated at 50-65%, with most attributable to HLA genes but substantial contributions from non-HLA loci.

Cigarette smoking is the most significant modifiable environmental risk factor for RA, conferring a 2-13 fold increased risk of disease development in smokers compared to never-smokers and substantially increasing anti-CCP antibody positivity even in asymptomatic individuals. The mechanism involves smoking-induced upregulation of PAD enzymes in the lung and oral mucosa, creating citrullinated autoantigens that prime autoreactive B and T cells; this pathway is supported by observations of subclinical lung inflammation and elevated anti-CCP antibody titers in smokers at risk for RA. Importantly, the risk of RA increases with cumulative smoking exposure and persists for years after smoking cessation, though quitting does reduce future risk. Smokers with RA have more severe disease, greater radiographic progression, and poorer response to anti-TNF therapy compared to non-smokers, indicating that smoking impacts both disease development and treatment response.

Periodontitis and poor oral hygiene are associated with increased RA risk, likely through mechanisms involving PAD enzyme activity in the inflamed oral mucosa and bacterial lipopolysaccharides triggering innate immunity; the periodontal pathogen Porphyromonas gingivalis produces a unique PAD enzyme that citrullinates both bacterial and host proteins, potentially creating a molecular mimicry scenario. Respiratory tract infections, particularly with atypical organisms, have been epidemiologically linked to RA onset, possibly through innate immune activation and bystander T cell activation. Dysbiosis of the gut microbiome has been described in RA patients, with reduced diversity and alterations in segmented filamentous bacteria and other organisms that normally promote IL-22 production and intestinal barrier integrity; these changes may increase intestinal permeability and bacterial translocation.

Women are 2.5-3 times more likely to develop RA than men, and disease incidence peaks during perimenopause and early postmenopause, suggesting that loss of estrogen protection contributes to disease pathogenesis. Estrogen normally enhances regulatory T cell (Treg) differentiation and function; declining estrogen levels may shift the balance toward effector T cell responses. Notably, pregnancy is often associated with RA remission due to immunological tolerance mechanisms and elevated progesterone; disease frequently flares postpartum when progesterone levels decline. Postmenopausal hormone replacement therapy is associated with slightly reduced RA risk, though the clinical significance of this association remains debated.

Peak RA incidence occurs in the 5th-6th decades, though the disease can develop at any age; seronegative RA tends to occur at older ages compared to seropositive RA. Elderly-onset RA (age >60 years at diagnosis) may present with more acute onset and higher systemic inflammatory markers compared to younger-onset disease.

Significant joint trauma and surgical interventions may increase local risk of RA development in that joint, suggesting that mechanical factors and associated local inflammatory responses can precipitate autoimmunity in genetically predisposed individuals.

RA typically presents as an insidious, progressive disease but may occasionally have acute onset; the cardinal feature is symmetrical polyarticular inflammation preferentially affecting small joints:

Patients characteristically develop bilateral, symmetrical pain and swelling of the metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints, and wrists early in disease; distal interphalangeal (DIP) joint involvement is atypical for RA and suggests alternative diagnoses such as osteoarthritis or psoriatic arthritis. Morning stiffness lasting >1 hour is a hallmark feature reflecting the accumulation of inflammatory mediators and edema within joints overnight and is dramatically more specific for inflammatory versus mechanical arthritis; patients often report worst symptoms upon awakening that gradually improve throughout the morning with activity. Joint pain is typically worse with rest and improves with activity initially (though this contrasts with mechanical joint disease where pain worsens with activity). As disease progresses, patients develop functional impairment affecting activities of daily living such as gripping objects, writing, dressing, and ambulation.

Early in disease, inflammation typically involves the small joints of the hands and feet symmetrically; as disease progresses, larger joints become involved including elbows, shoulders, knees, ankles, and cervical spine. The feet and ankles are involved in up to 90% of RA patients, often with metatarsophalangeal (MTP) joint pain that may cause gait disturbance and difficulty wearing shoes. Thoracic and lumbar spine involvement is less common than cervical involvement; when axial disease occurs, it typically affects the atlantoaxial joint with risk of atlantoaxial subluxation in patients with long-standing disease. Constitutional symptoms including low-grade fever, fatigue, and malaise commonly accompany the joint symptoms, reflecting systemic inflammation.

Joint swelling and warmth are typically present over inflamed joints; the swelling is usually soft tissue (synovial thickening and effusion) rather than bony enlargement, which distinguishes RA from osteoarthritis. Tenderness to palpation is marked and distinguishes actively inflamed joints from those with chronic changes; palpable synovial thickening and boggy swelling of the MCP and PIP joints bilaterally is classic. Loss of active and passive range of motion develops as pain and inflammation limit movement; fixed flexion contractures of the fingers may develop with chronic disease. Grip strength is markedly diminished, both due to pain and inflammation and due to underlying muscular changes. Joint deformities develop in patients with longstanding disease, including swan-neck deformity (hyperextension of the PIP joint with flexion of the DIP joint due to intrinsic muscle tightness and extrinsic extensor imbalance), boutonnière deformity (PIP flexion with DIP extension), Z-thumb deformity (MCP flexion with interphalangeal extension), and ulnar deviation of the fingers (from a combination of MCP varus deviation and carpal subluxation related to pannus erosion and chronic inflammation).

Rheumatoid nodules are subcutaneous nodules that develop in 20-30% of seropositive RA patients, typically over pressure points such as the extensor surface of the elbows, the Achilles tendons, and the dorsal surfaces of the hands; they consist histologically of central necrosis surrounded by palisading macrophages. Nodules may ulcerate and become infected. Rheumatoid vasculitis is a serious complication affecting small and medium vessels, presenting as digital infarcts, palpable purpura, mononeuritis multiplex, or mesenteric ischemia; it is associated with high RF titers and seropositive disease. Pulmonary involvement occurs in up to 50% of RA patients and includes: pleural inflammation and small pleural effusions, pulmonary fibrosis (usually interstitial lung disease with usual interstitial pneumonia pattern), increased prevalence of bronchiectasis, pulmonary nodules that may resemble rheumatoid nodules, and Caplan syndrome (progressive massive fibrosis in patients with occupational lung exposure such as silicosis or coal dust). Cardiac manifestations include increased risk of atherosclerotic cardiovascular disease (independent of traditional risk factors), pericarditis with potential for constriction, and accelerated myocardial disease. Ocular involvement includes episcleritis and scleritis (the latter being associated with aggressive disease and risk of perforation if untreated). Felty syndrome (the triad of RA, hepatosplenomegaly, and neutropenia) occurs in <5% of patients with longstanding seropositive disease and is associated with increased infection risk and often improved by TNF-α inhibitor therapy.

Approximately 20-30% of RA patients are seronegative (negative for both RF and anti-CCP antibodies); these patients typically have milder disease, slower radiographic progression, and better long-term prognosis compared to seropositive patients, though they remain at risk for joint damage if disease is inadequately treated. Seronegative disease may take longer to diagnose and should be distinguished from other seronegative polyarthritides.

The diagnosis of RA is based on clinical assessment integrated with laboratory and imaging findings; early diagnosis within the first 3 months of symptom onset ("window of opportunity") is critical because early aggressive treatment with DMARDs can prevent irreversible joint damage:

The 2010 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) classification criteria constitute a validated diagnostic and classification tool that scores four domains: joint involvement (0-3 points), serology—RF or anti-CCP status (0-3 points), acute-phase reactants—ESR or CRP (0-1 point), and symptom duration ≥6 weeks (0-1 point). A score ≥6/10 meets criteria for classification as RA; these criteria are designed for research and early diagnosis rather than as strict diagnostic requirements in clinical practice. Critically

Goal of therapy — treat-to-target: the American College of Rheumatology (ACR) 2021 RA treatment guideline and EULAR both endorse a treat-to-target strategy: start a DMARD as soon as the diagnosis is made, measure disease activity with a validated composite index, and escalate every few months until low disease activity or remission is achieved. Delay costs erosions, which do not remodel.

Definitive/surgical: synovectomy, tendon repair, arthrodesis, and total joint arthroplasty for end-stage structural damage; C1–C2 fusion for symptomatic atlantoaxial subluxation.